Is iBio, Inc. (IBIO) a Buy, Sell, or Hold?
NASDAQ : IBIO
iBio, Inc. — News
$1.41 USD
$0.02 (1.44%)
- Volume
- 435.93K
- Average Volume
- 960.55K
- Market Capitalization
- $22.26M
- P/E Ratio
- -2.45
- Dividend Yield
- 0.00%
- Price Target
- $5.00
- Year High
- $3.82
- Year Low
- $0.57
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $11.88
| Source | Headline |
|---|---|
|
iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer
SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced the appointment of Molly Carr, M.D., as Chief Medical Officer, further strengthening its executive leadership as the company advances its clinical-stage cardiometabolic pipeline. An experienced physician with over 30 years of clinical, academic and biopharmaceutical experience in endocrinology and metabolic disease, Dr. Carr will lead the company's global clinical strategy, medical affairs, and regulatory initiatives as it advances its pipeline toward late-stage development. globenewswire.com - 2026-08-04 07:00:00 |
|
iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study
Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach globenewswire.com - 2026-07-01 07:00:00 |
|
iBio to Participate in Upcoming Healthcare Investor Conferences
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO) (“iBio” or the “Company”), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced that Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer, and Felipe Duran, Chief Financial Officer, will participate in the Jefferies Global Healthcare Conference and the Leerink Partners Therapeutics Forum: I&I and Metabolism Conference. globenewswire.com - 2026-06-02 16:01:00 |
|
iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity
IBIO-600 is potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition globenewswire.com - 2026-06-02 07:00:00 |
|
iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update
Received regulatory clearance to initiate its Phase 1 clinical trial of IBIO-600 in Australia Announced a strategic pipeline expansion into pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) of its bispecific antibody Reported new preclinical data from its obese non-human primate (NHP) study evaluating IBIO-610, with visceral fat reduced by 6.7% and total fat mass by 5.2% SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today reported financial results for the third quarter ended Mar. 31, 2026, and provided a corporate update on its progress. “This last quarter was marked by significant advancement across our full pipeline. globenewswire.com - 2026-05-12 16:05:00 |
